Literature DB >> 19675314

Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50) values.

Ben-Fillippo Krippendorff1, Roland Neuhaus, Philip Lienau, Andreas Reichel, Wilhelm Huisinga.   

Abstract

The potential of enzyme inhibition of a drug is frequently quantified in terms of IC(50) values. Although this is a suitable quantity for reversible inhibitors, concerns arise when dealing with irreversible or mechanism-based inhibitors (MBIs). IC(50) values of MBIs are time dependent, causing serious problems when aiming at ranking different compounds with respect to their inhibitory potential. As a consequence, most studies and ranking schemes related to MBIs rely on the inhibition constant (K(I)) and the rate of enzyme inactivation (k(inact)) rather than on IC(50) values. In this article, the authors derive a novel relation between potentially time-dependent IC(50) values and K(I), k(inact) parameters for different types of inhibition. This allows for direct estimation of K(I) and k(inact) values from time-dependent IC(50) values, even without the need of additional preincubation experiments. The application of this approach is illustrated using a fluorimetric assay to access the drug-drug interaction potential associated with new chemical entities. The approach can easily be implemented using standard software tools (e.g., XLfit) and may also be suitable for applications where mechanism-based inhibition is a desired mode of action (e.g., at particular pharmacological drug targets).

Mesh:

Substances:

Year:  2009        PMID: 19675314     DOI: 10.1177/1087057109336751

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  21 in total

1.  Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor.

Authors:  Yudao Shen; Fengling Li; Magdalena M Szewczyk; Levon Halabelian; Kwang-Su Park; Irene Chau; Aiping Dong; Hong Zeng; He Chen; Fanye Meng; Dalia Barsyte-Lovejoy; Cheryl H Arrowsmith; Peter J Brown; Jing Liu; Masoud Vedadi; Jian Jin
Journal:  J Med Chem       Date:  2020-05-14       Impact factor: 7.446

2.  Covalent Antiviral Agents.

Authors:  Sako Mirzaie; Fatemeh Abdi; Amin GhavamiNejad; Brian Lu; Xiao Yu Wu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Mechanistic enzymology in drug discovery: a fresh perspective.

Authors:  Geoffrey A Holdgate; Thomas D Meek; Rachel L Grimley
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

Review 4.  Covalent inhibition of protein tyrosine phosphatases.

Authors:  Kasi Viswanatharaju Ruddraraju; Zhong-Yin Zhang
Journal:  Mol Biosyst       Date:  2017-06-27

5.  β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology.

Authors:  Christina M Ridley; Karen E Thur; Jessica Shanahan; Nagendra Babu Thillaiappan; Ann Shen; Karly Uhl; Charlotte M Walden; Ahad A Rahim; Simon N Waddington; Frances M Platt; Aarnoud C van der Spoel
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

6.  Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis.

Authors:  Philippe Egesborg; Hélène Carlettini; Jordan P Volpato; Nicolas Doucet
Journal:  Protein Sci       Date:  2014-12-30       Impact factor: 6.725

7.  Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis.

Authors:  Wan Seok Yang; Katherine J Kim; Michael M Gaschler; Milesh Patel; Mikhail S Shchepinov; Brent R Stockwell
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-09       Impact factor: 11.205

8.  Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.

Authors:  Frank E Kwarcinski; Christel C Fox; Michael E Steffey; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2012-09-05       Impact factor: 5.100

9.  A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.

Authors:  Konstantinos Biliouris; Ivan Nestorov; Himanshu Naik; David Dai; Guangqing Xiao; Qin Wang; Alex Pellerin; Dania Rabah; Lawrence J Lesko; Mirjam N Trame
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-30       Impact factor: 2.745

Review 10.  Recent advances in the development of covalent inhibitors.

Authors:  Hyunsoo Kim; Yoon Soo Hwang; Mingi Kim; Seung Bum Park
Journal:  RSC Med Chem       Date:  2021-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.